Supernus Pharmaceuticals, Inc. (SUPN)
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
- Symbol
- SUPN
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $2.54B
- 52 week range
- 40.51 - 59.68
Valuation
- Share price
- $43.39 (close of 2026-09-23)
- P/E (TTM)
- -22.79x
- Price to book
- 2.47x
- Price to free cash flow
- 135.45x
- Enterprise value
- $2.40B
- Book value per share
- $17.73
Price performance
| Period | Change |
|---|
| 1 day | +1.43% |
| 5 days | +5.11% |
| 1 month | -5.37% |
| 3 months | -2.45% |
| 6 months | -11.90% |
| Year to date | -12.70% |
| 1 year | -7.35% |
| 3 years | +54.03% |
| 5 years | +61.12% |
| 10 years | +65.80% |
| All time | +708.01% |
Profitability and growth
- Return on equity
- -3.63%
- Return on invested capital
- -5.32%
- Return on assets
- -2.65%
- Return on capital employed
- -5.59%
- Gross margin
- 89.63%
- Net margin
- -5.36%
- EBITDA margin
- 4.07%
- Revenue growth
- 8.63%
- Net income growth
- -152.19%
- Free cash flow growth
- -73.14%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 0.74%
- Current ratio
- 2.08x
- Net debt to EBITDA
- 7.70x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $718.95M
- Cost of revenue
- $74.56M
- Gross profit
- $644.39M
- EBITDA
- $29.28M
- Net income
- $-38.55M
- Earnings per share
- $-0.68
- Research and development
- $106.23M
- Shares outstanding
- 56.45M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $718.95M | $644.39M | $-38.55M | $-0.68 |
| 2024-12-31 | $661.82M | $583.91M | $73.86M | $1.34 |
| 2023-12-31 | $607.52M | $523.74M | $1.32M | $0.02 |
| 2022-12-31 | $667.24M | $580.02M | $60.71M | $1.13 |
| 2021-12-31 | $579.77M | $481.25M | $53.42M | $1.01 |
| 2020-12-31 | $520.40M | $467.94M | $126.95M | $2.41 |
| 2019-12-31 | $392.75M | $376.10M | $113.06M | $2.16 |
| 2018-12-31 | $408.90M | $393.54M | $110.99M | $2.13 |
| 2017-12-31 | $302.24M | $287.02M | $57.28M | $1.13 |
| 2016-12-31 | $215.00M | $203.02M | $91.22M | $1.84 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 89.63% | -5.36% | -3.63% | -5.32% |
| 2024-12-31 | 88.23% | 11.16% | 7.13% | 5.76% |
| 2023-12-31 | 86.21% | 0.22% | 0.14% | -0.59% |
| 2022-12-31 | 86.93% | 9.10% | 6.85% | 3.72% |
| 2021-12-31 | 83.01% | 9.21% | 6.55% | 10.04% |
| 2020-12-31 | 89.92% | 24.39% | 17.04% | 25.75% |
| 2019-12-31 | 95.76% | 28.79% | 18.99% | 25.52% |
| 2018-12-31 | 96.24% | 27.14% | 24.50% | 44.20% |
| 2017-12-31 | 94.97% | 18.95% | 21.42% | 33.62% |
| 2016-12-31 | 94.43% | 42.43% | 47.57% | 43.25% |
Cash and debt by year
| Period end | Cash |
|---|
| 2025-12-31 | $128.45M |
| 2024-12-31 | $69.33M |
| 2023-12-31 | $75.05M |
| 2022-12-31 | $93.12M |
| 2021-12-31 | $203.43M |
| 2020-12-31 | $288.64M |
| 2019-12-31 | $181.38M |
| 2018-12-31 | $192.25M |
| 2017-12-31 | $100.30M |
| 2016-12-31 | $66.40M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $45.99M | $33.05M |
| 2024-12-31 | $171.23M | $27.75M |
| 2023-12-31 | $110.53M | $26.76M |
| 2022-12-31 | $116.41M | $17.57M |
| 2021-12-31 | $127.13M | $17.91M |
| 2020-12-31 | $134.95M | $16.56M |
| 2019-12-31 | $140.39M | $14.85M |
| 2018-12-31 | $128.14M | $11.29M |
| 2017-12-31 | $112.61M | $8.43M |
| 2016-12-31 | $65.21M | $5.93M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-03
- Consensus EPS estimate
- $0.66
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-03 | Jun/2026 | $0.30 |
| 2026-05-05 | - | - |
| 2026-02-24 | - | - |
| 2025-11-04 | - | - |
| 2025-08-05 | - | - |
| 2025-05-06 | - | - |
| 2025-02-25 | - | - |
| 2024-11-04 | - | - |
Filings and sources
- Company website
- supernus.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Zoetis Inc. (ZTS) · Viatris Inc (VTRS) · Hims & Hers Health, Inc. (HIMS) · Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades